Alchemia Ltd. is a biotechnology company, which engages in developing new human therapeutics based on its proprietary drug discovery, drug targeting and synthesis technologies. It involves in the research and development of new human pharmaceuticals. The company also engages in the commercialization and improvements of its generic fondaparinux product. Its products include fondaparinux sodium, hyact and ha-irinotecan. Alchemia was founded by Tracie Rams dale in 1995 and is headquartered in Melbourne, Australia.